Cyclophosphamide: Dermatology Uses, Dosing, And Key Precautions

Cyclophosphamide is a potent alkylating agent and immunosuppressive medication primarily used in oncology and rheumatology, with established off-label applications in dermatology for severe, refractory autoimmune and inflammatory skin diseases. Introduced in the 1950s, it exerts cytotoxic effects by cross-linking DNA strands, inhibiting cell division, and suppressing immune responses, particularly T-cell activity. In dermatology, it serves as a rescue therapy when first-line treatments like corticosteroids, mycophenolate, or rituximab fail, particularly in life- or organ-threatening conditions such as pemphigus vulgaris or ANCA-associated vasculitis with extensive cutaneous involvement.

While effective, its use demands specialist oversight due to significant toxicity risks, including myelosuppression, hemorrhagic cystitis, infertility, and secondary malignancies. Pulse intravenous regimens have improved its safety profile over continuous oral dosing, reducing cumulative exposure. This article details its dermatologic applications, dosing protocols, monitoring requirements, and adverse effects, drawing from clinical reviews and guidelines.

What is cyclophosphamide?

Cyclophosphamide (trade name Cycloblastin™ in New Zealand) is a prodrug activated in the liver to 4-hydroxycyclophosphamide and aldophosphamide, which generate phosphoramide mustard—the active alkylating metabolite. This agent adds alkyl groups to DNA guanine, causing inter- and intra-strand cross-links that halt replication and transcription, leading to cell death. Selectively toxic to rapidly proliferating cells, it targets lymphocytes, making it immunosuppressive at lower doses and antineoplastic at higher ones.

Available as 50 mg oral tablets or lyophilized powder for IV reconstitution (vials of 500 mg, 1 g, or 2 g), it is FDA-approved for malignancies (e.g., lymphomas, leukemias, breast/ovarian cancers, neuroblastoma) and pediatric nephrotic syndrome refractory to steroids. Dermatologic uses are off-label but supported by case series, cohort studies, and expert consensus.

Who is cyclophosphamide used for in dermatology?

Cyclophosphamide is reserved for severe, refractory autoimmune skin diseases or those with systemic involvement unresponsive to safer agents. Key indications include:

• Autoimmune blistering disorders: Pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, mucous membrane pemphigoid, epidermolysis bullosa acquisita, and bullous systemic lupus erythematosus (BSLE). Pulse IV regimens (e.g., with dexamethasone) achieve remission in 70-90% of refractory pemphigus cases.
• Connective tissue diseases with skin manifestations: Systemic lupus erythematosus (SLE) with severe cutaneous or renal involvement, dermatomyositis (especially amyopathic or refractory forms), and systemic sclerosis (progressive cutaneous fibrosis).
• Vasculitis: ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis), polyarteritis nodosa, and cryoglobulinemic vasculitis with major skin lesions.
• Other: Refractory cutaneous lupus erythematosus, pyoderma gangrenosum, and cutaneous T-cell lymphoma (CTCL/mycosis fungoides) in advanced stages.

Typically combined with corticosteroids; rituximab often preferred now, but cyclophosphamide remains vital for acute, organ-threatening flares.

What does cyclophosphamide treat?

Success rates: Remission in 60-80% of severe pemphigus; skin improvement in 50-70% of vasculitis cases with low-dose pulses.

How is cyclophosphamide used?

Used orally or IV, always under specialist supervision. Pre-treatment baseline includes FBC, U&E, LFTs, urine microscopy/cytology, pregnancy test (women of childbearing potential), and viral serology (HBV, HCV, HIV, VZV).

• Oral dosing: 1-2 mg/kg/day (max 5 mg/kg/day), adjusted to leukocyte nadir (target 3-4 x 10⁹/L). Used short-term for induction.
• IV pulse: 500-1000 mg/m² every 4 weeks for 6 months, then taper. Preferred in dermatology for lower toxicity; often with methylprednisolone pulses.

Hydration (2-3 L/day) and mesna (uroprotectant) mandatory for IV doses to prevent hemorrhagic cystitis. Anti-emetics (ondansetron) for nausea. Monitor FBC weekly initially, then biweekly; urine weekly for hematuria.

Precautions when using cyclophosphamide

• Contraindications: Active infection, pregnancy (teratogenic), breastfeeding, urinary obstruction, prior hemorrhagic cystitis.
• Hydration: Minimum 2 L fluid/day; avoid if cardiac/renal impairment.
• Vaccinations: Live vaccines contraindicated; update inactivated vaccines pre-treatment.
• Fertility: Counsel on sperm/ovum cryopreservation; risk highest >7.5 g cumulative dose.
• Infections: Prophylaxis (trimethoprim-sulfamethoxazole for Pneumocystis) if lymphopenic.

Drug interactions with cyclophosphamide

Additive myelosuppression with other cytotoxics (methotrexate, azathioprine); increased toxicity with CYP2B6 inducers (phenobarbital, rifampin). Succinylcholine potentiation risks prolonged apnea. Allopurinol increases myelosuppression.

Pregnancy, breastfeeding, and fertility

Category D: Teratogenic (neural tube defects, growth retardation). Contraindicated in pregnancy; effective contraception mandatory (barrier + hormonal). Passes into breast milk—discontinue breastfeeding. Gonadal toxicity: Amenorrhea in 30-60% women (>40 years higher risk), azoospermia in 50% men. Dose/duration-dependent; often reversible if <6 g cumulative.

Side effects of cyclophosphamide

Dose-limiting: Myelosuppression (leukopenia nadir days 8-12, recover by week 4).

• Common (>10%): Nausea/vomiting (30-50%), alopecia (reversible, 30-40%), myelosuppression (60-70%), infections (20-25%), hemorrhagic cystitis (10-20% without mesna).
• Serious: Secondary bladder cancer (5% at >20-30 g cumulative), infertility (30-60%), pulmonary fibrosis/cardiotoxicity (<2%), SIADH.

Frequently Asked Questions

What monitoring is required on cyclophosphamide?

Weekly FBC (days 8-12 initially), urine for blood/RBCs, U&E/LFTs monthly, cystoscopy if persistent hematuria. Annual urothelial surveillance post-treatment.

Can cyclophosphamide cause cancer?

Yes, bladder cancer risk rises with cumulative dose >20 g; also leukemias/lymphomas. Minimize exposure.

Is hair loss permanent?

No, alopecia is reversible 2-3 months post-discontinuation.

How long until side effects resolve?

Myelosuppression recovers 3-4 weeks; cystitis variable; infertility may be permanent.

Is cyclophosphamide safe in elderly?

Use cautiously—higher toxicity risk; prefer pulses.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb